Precision therapy before surgery for HR-positive breast cancer
This trial tests a new precision therapy given before surgery for women with a specific type of HR-positive breast cancer. It aims to see if this treatment can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have been diagnosed with HR-positive/HER2-negative breast cancer (a common type).
- Your tumor has a specific molecular subtype called SNF2/3/4.
- You have not had any prior treatment for breast cancer (like chemotherapy, hormone therapy, or radiation).
- Your cancer is not stage IV (has not spread to other parts of the body).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QL1706 combined with chemotherapy given before surgery for people with early-stage, high-risk breast cancer that is estrogen receptor positive (ER+) and HER2 negative. The goal is to see if this combination can shrink tumors more effectively before surgery.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests whether a customized treatment plan given before surgery can improve outcomes for women with early-stage HR-positive, HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.